Jupiter Life Line Hospitals Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target
- July 6, 2026
- Posted by: Kunal Singla
- Category: News
Jupiter Life Line Hospitals CMP Rs.1,455. Q1 FY27E revenue Rs.393-452 Cr. PAT estimate Rs.43-55 Cr. 12-month target Rs.1,608-1,798.
Jupiter Life Line Hospitals Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Jupiter Life Line Hospitals shares trading at Rs.1,455 against a market capitalisation of Rs.9,539 Cr and a price-to-earnings multiple of 49.1. As a healthcare services name on the NSE and BSE, Jupiter Life Line Hospitals enters the Jupiter Life Line Hospitals Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.
This Jupiter Life Line Hospitals Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.366 Cr revenue and Rs.44 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.
Get Free Investment Predictions and Jupiter Life Line Hospitals Research at Univest
About Jupiter Life Line Hospitals
Jupiter Life Line Hospitals (NSE: JLHL) operates in the healthcare services space and is tracked on Univest under its NSE and BSE listings. Ahead of the Jupiter Life Line Hospitals Q1 Results FY27 print, the company’s most recent reported quarter (Q4 FY26) shows revenue of Rs.397 Cr and net profit of Rs.50 Cr, forming the base against which the Jupiter Life Line Hospitals Q1 Results FY27 estimates in this article are built. This Jupiter Life Line Hospitals Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.
Jupiter Life Line Hospitals Q1 FY27 Estimates
| Metric | Q1 FY27E (Range) | Q1 FY26 Actual | YoY Growth |
|---|---|---|---|
| Revenue (Rs. Cr) | 393-452 | 366 | +15.6% |
| Net Profit / PAT (Rs. Cr) | 43-55 | 44 | +11.0% |
| Results Date | July-August 2026 (indicative) | ||
| 12-Month Target (Uniresearch Estimate) | Rs.1,608-1,798 | ||
Key Catalysts to Watch
1. Occupancy and ARPOB Trends
Occupancy and ARPOB improvement across hospital and diagnostic networks is one of the primary variables that analysts are tracking ahead of Jupiter Life Line Hospitals’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Jupiter Life Line Hospitals share price target or faces renewed pressure.
2. Capacity Addition
Capacity addition through new beds or centres supporting medium-term growth is one of the primary variables that analysts are tracking ahead of Jupiter Life Line Hospitals’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Jupiter Life Line Hospitals share price target or faces renewed pressure.
3. Case Mix Improvement
Case mix improvement toward higher-margin specialties aiding profitability is one of the primary variables that analysts are tracking ahead of Jupiter Life Line Hospitals’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Jupiter Life Line Hospitals share price target or faces renewed pressure.
Download the Univest iOS App or Univest Android App to track Jupiter Life Line Hospitals’s live price and Q1 FY27 result updates.
Key Risks to the Jupiter Life Line Hospitals Q1 Results FY27 Outlook
- Slower occupancy ramp-up in newly added capacity affecting near-term margins.
- Regulatory changes to pricing or insurance reimbursement norms.
- Talent cost inflation for specialist doctors and clinical staff.
Q4 FY26 Performance Context for the Jupiter Life Line Hospitals Q1 Results FY27 Print
Jupiter Life Line Hospitals closed Q4 FY26 with revenue of Rs.397 Cr and net profit of Rs.50 Cr, a year-on-year revenue change of +15.6% and PAT change of +11.0% versus Q4 FY25. This base underpins the Jupiter Life Line Hospitals Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Jupiter Life Line Hospitals Q1 Results FY27 commentary once reported.
Technical Analysis Ahead of Jupiter Life Line Hospitals Q1 Results FY27
Jupiter Life Line Hospitals shares last traded at Rs.1,455. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.
Share Price Target Based on the Jupiter Life Line Hospitals Q1 Results FY27 Outlook
3-6 Month Target
Over a 3-6 month horizon, the Jupiter Life Line Hospitals Q1 Results FY27 trailing-growth framework points to a range of Rs.1,476-1,592 for Jupiter Life Line Hospitals, contingent on the Jupiter Life Line Hospitals Q1 Results FY27 print matching or beating the trailing growth trend.
12-Month Target
The 12-month target (Uniresearch estimate) tied to this Jupiter Life Line Hospitals Q1 Results FY27 view for Jupiter Life Line Hospitals works out to Rs.1,608-1,798, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Jupiter Life Line Hospitals Q1 Results FY27, not a formal Buy or Sell call.
FY27-28 Outlook
Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Jupiter Life Line Hospitals Q1 Results FY27 analysis would put Jupiter Life Line Hospitals in a Rs.1,773-2,035 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.
What to Watch in the Jupiter Life Line Hospitals Q1 Results FY27 Print
- Revenue and PAT versus the Jupiter Life Line Hospitals Q1 Results FY27 estimate range in this preview.
- Management commentary on FY27 growth guidance and margin trajectory relevant to the Jupiter Life Line Hospitals Q1 Results FY27 narrative.
- Occupancy and ARPOB improvement across hospital and diagnostic networks
- Slower occupancy ramp-up in newly added capacity affecting near-term margins
Conclusion on Jupiter Life Line Hospitals Q1 Results FY27
Jupiter Life Line Hospitals enters the Q1 FY27 results season trading at Rs.1,455, with the 12-month Uniresearch target range of Rs.1,608-1,798 reflecting a tracking with a constructive bias stance. Investors tracking the Jupiter Life Line Hospitals Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Jupiter Life Line Hospitals Q1 Results FY27
When are Jupiter Life Line Hospitals Q1 FY27 results expected?
Ans. Jupiter Life Line Hospitals’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.
What is the Jupiter Life Line Hospitals Q1 FY27 revenue estimate?
Ans. The Uniresearch trailing-growth estimate for Jupiter Life Line Hospitals’s Q1 FY27 revenue is Rs.393-452 Cr, based on the Q1 FY26 base of Rs.366 Cr.
What is the Jupiter Life Line Hospitals share price target?
Ans. The 12-month Uniresearch estimate for Jupiter Life Line Hospitals share price target is Rs.1,608-1,798, based on trailing growth and current valuation multiples.
Is Jupiter Life Line Hospitals a good buy before Q1 FY27 results?
Ans. Jupiter Life Line Hospitals is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.
What should investors watch in Jupiter Life Line Hospitals’s Q1 FY27 results?
Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and occupancy and ARPOB improvement across hospital and diagnostic networks.
Where can I track Jupiter Life Line Hospitals share price live?
Ans. Jupiter Life Line Hospitals share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.
